Safety and efficacy of delpacibart zotadirsen in Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the USA (EXPLORE44): a randomised, placebo-controlled, double-blind, phase 1/2 trial
Safety and efficacy of delpacibart zotadirsen in Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the USA (EXPLORE44): a randomised, placebo-controlled, double-blind, phase 1/2 trial. // The Lancet Neurology. – URL: https://www.sciencedirect.com/science/article/pii/S1474442226003376?dgcid=rss_sd_all
Safety and efficacy of delpacibart zotadirsen in Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the USA (EXPLORE44): a randomised, placebo-controlled, double-blind, phase 1/2 trial. The Lancet Neurology. https://www.sciencedirect.com/science/article/pii/S1474442226003376?dgcid=rss_sd_all
“Safety and efficacy of delpacibart zotadirsen in Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the USA (EXPLORE44): a randomised, placebo-controlled, double-blind, phase 1/2 trial.” The Lancet Neurology.
@article{article68763,
title = {Safety and efficacy of delpacibart zotadirsen in Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the USA (EXPLORE44): a randomised, placebo-controlled, double-blind, phase 1/2 trial},
journal = {The Lancet Neurology},
url = {https://www.sciencedirect.com/science/article/pii/S1474442226003376?dgcid=rss_sd_all}
}